BACKGROUND: Cranial radiotherapy (CRT) is a known risk factor for neurocognitive impairment in survivors of childhood cancer and may increase risk for mild cognitive impairment and dementia in adulthood. METHODS: We performed a cross-sectional evaluation of survivors of childhood acute lymphoblastic leukemia (ALL) treated with 18 Gy (n = 127) or 24 Gy (n = 138) CRT. Impairment (age-adjusted score >1 standard deviation below expected mean, two-sided exact binomial test) on the Wechsler Memory Scale IV (WMS-IV) was measured. A subset of survivors (n = 85) completed structural and functional neuroimaging. RESULTS: Survivors who received 24 Gy, but not 18 Gy, CRT had impairment in immediate (impairment rate = 33.8%, 95% confidence interval [CI] = 25.9% to 42.4%; P < .001) and delayed memory (impairment rate = 30.2%, 95% CI = 22.6% to 38.6%; P < .001). The mean score for long-term narrative memory among survivors who received 24 Gy CRT was equivalent to that for individuals older than 69 years. Impaired immediate memory was associated with smaller right (P = .02) and left (P = .008) temporal lobe volumes, and impaired delayed memory was associated with thinner parietal and frontal cortices. Lower hippocampal volumes and increased functional magnetic resonance imaging activation were observed with memory impairment. Reduced cognitive status (Brief Cognitive Status Exam from the WMS-IV) was identified after 24 Gy (18.5%, 95% CI = 12.4% to 26.1%; P < .001), but not 18 Gy (8.7%, 95% CI = 4.4% to 15.0%; P = .11), CRT, suggesting a dose-response effect. Employment rates were equivalent (63.8% for 24 Gy CRT and 63.0% for 18 Gy CRT). CONCLUSIONS: Adult survivors who received 24 Gy CRT had reduced cognitive status and memory, with reduced integrity in neuroanatomical regions essential in memory formation, consistent with early onset mild cognitive impairment.
BACKGROUND: Cranial radiotherapy (CRT) is a known risk factor for neurocognitive impairment in survivors of childhood cancer and may increase risk for mild cognitive impairment and dementia in adulthood. METHODS: We performed a cross-sectional evaluation of survivors of childhood acute lymphoblastic leukemia (ALL) treated with 18 Gy (n = 127) or 24 Gy (n = 138) CRT. Impairment (age-adjusted score >1 standard deviation below expected mean, two-sided exact binomial test) on the Wechsler Memory Scale IV (WMS-IV) was measured. A subset of survivors (n = 85) completed structural and functional neuroimaging. RESULTS: Survivors who received 24 Gy, but not 18 Gy, CRT had impairment in immediate (impairment rate = 33.8%, 95% confidence interval [CI] = 25.9% to 42.4%; P < .001) and delayed memory (impairment rate = 30.2%, 95% CI = 22.6% to 38.6%; P < .001). The mean score for long-term narrative memory among survivors who received 24 Gy CRT was equivalent to that for individuals older than 69 years. Impaired immediate memory was associated with smaller right (P = .02) and left (P = .008) temporal lobe volumes, and impaired delayed memory was associated with thinner parietal and frontal cortices. Lower hippocampal volumes and increased functional magnetic resonance imaging activation were observed with memory impairment. Reduced cognitive status (Brief Cognitive Status Exam from the WMS-IV) was identified after 24 Gy (18.5%, 95% CI = 12.4% to 26.1%; P < .001), but not 18 Gy (8.7%, 95% CI = 4.4% to 15.0%; P = .11), CRT, suggesting a dose-response effect. Employment rates were equivalent (63.8% for 24 Gy CRT and 63.0% for 18 Gy CRT). CONCLUSIONS: Adult survivors who received 24 Gy CRT had reduced cognitive status and memory, with reduced integrity in neuroanatomical regions essential in memory formation, consistent with early onset mild cognitive impairment.
Authors: S Y Bookheimer; M H Strojwas; M S Cohen; A M Saunders; M A Pericak-Vance; J C Mazziotta; G W Small Journal: N Engl J Med Date: 2000-08-17 Impact factor: 91.245
Authors: Wendy Landier; Smita Bhatia; Debra A Eshelman; Katherine J Forte; Teresa Sweeney; Allison L Hester; Joan Darling; F Daniel Armstrong; Julie Blatt; Louis S Constine; Carolyn R Freeman; Debra L Friedman; Daniel M Green; Neyssa Marina; Anna T Meadows; Joseph P Neglia; Kevin C Oeffinger; Leslie L Robison; Kathleen S Ruccione; Charles A Sklar; Melissa M Hudson Journal: J Clin Oncol Date: 2004-12-02 Impact factor: 44.544
Authors: Kevin R Krull; Nan Zhang; Aimee Santucci; Deo Kumar Srivastava; Matthew J Krasin; Larry E Kun; Ching-Hon Pui; Leslie L Robison; Melissa M Hudson; Gregory T Armstrong Journal: Blood Date: 2013-06-06 Impact factor: 22.113
Authors: Kirsten K Ness; Gregory T Armstrong; Mondira Kundu; Carmen L Wilson; Tamara Tchkonia; James L Kirkland Journal: Cancer Date: 2014-12-19 Impact factor: 6.860
Authors: Gregory T Armstrong; Toana Kawashima; Wendy Leisenring; Kayla Stratton; Marilyn Stovall; Melissa M Hudson; Charles A Sklar; Leslie L Robison; Kevin C Oeffinger Journal: J Clin Oncol Date: 2014-03-17 Impact factor: 44.544
Authors: Tara M Brinkman; E Anne Lown; Chenghong Li; Ingrid Tonning Olsson; Jordan Gilleland Marchak; Margaret L Stuber; Stefanie Vuotto; Deokumar Srivastava; Paul C Nathan; Wendy M Leisenring; Gregory T Armstrong; Leslie L Robison; Kevin R Krull Journal: Addiction Date: 2018-10-19 Impact factor: 6.526
Authors: Michelle N Edelmann; Kevin R Krull; Wei Liu; John O Glass; Qing Ji; Robert J Ogg; Noah D Sabin; Deo Kumar Srivastava; Leslie L Robison; Melissa M Hudson; Wilburn E Reddick Journal: Brain Date: 2014-08-13 Impact factor: 13.501
Authors: Kelly M Kenzik; I-Chan Huang; Tara M Brinkman; Brandon Baughman; Kirsten K Ness; Elizabeth A Shenkman; Melissa M Hudson; Leslie L Robison; Kevin R Krull Journal: Neuropsychology Date: 2014-06-16 Impact factor: 3.295